UCB to buy Candid Therapeutics for 2.2 billion dollars
UCB agreed to buy Candid Therapeutics for up to 2.2 billion dollars. The deal includes 2 billion upfront for the California-based autoimmune drug developer.
UCB SA will acquire United States-based Candid Therapeutics for up to $2.2B to expand its autoimmune disease portfolio. The deal includes a $2B upfront payment and $200M in potential future milestone payments for the biotech firm. This acquisition signals the Belgium-based firm's pivot toward high-growth immunology assets to offset upcoming patent expirations.
### Scaling Autoimmune Portfolios UCB will pay $2B immediately to acquire the privately-held Candid Therapeutics. The agreement includes an additional $200M contingent on specific development milestones. UCB and Candid Therapeutics announced the deal late evening on May 3.
